Imagine your immune system turning on you so fiercely that it looks like a different, deadly disease. That's what happened to a 59-year-old man with a 10-year history of Sjögren's disease, an autoimmune condition, who also had a related liver problem called primary biliary cholangitis. He developed TAFRO syndrome, a life-threatening flood of inflammatory signals that can be mistaken for a similar condition called HLH.
Doctors first tried high-dose corticosteroids, intravenous immunoglobulin, and a combination of dexamethasone and ruxolitinib. He didn't respond to any of them. As a salvage option, the team turned to a four-drug chemotherapy regimen called RPAD: rituximab, bortezomib, doxorubicin, and dexamethasone.
That worked. The treatment brought his disease under control and led to a sustained clinical remission, with his platelet count back to normal at a 12-month follow-up.
Here's the honest part: this is a single case report. One patient. There was no comparison group, and the authors can't say the chemo caused the remission, only that it followed. The report also doesn't mention side effects or how well he tolerated the treatment. The researchers say TAFRO can hide behind chronic autoimmune disease and be mistaken for refractory HLH, so spotting it early matters. For now, RPAD is a possible salvage option worth studying, not a proven fix.
Common questions
What is TAFRO syndrome?
TAFRO syndrome is a rare condition where the immune system releases a flood of inflammatory signals. It can be life-threatening and may be mistaken for a similar condition called HLH. In this case, it arose in a 59-year-old man who already had Sjögren's disease and primary biliary cholangitis, both autoimmune conditions.
What is the RPAD regimen?
RPAD is a four-drug chemotherapy combination: rituximab, bortezomib, doxorubicin, and dexamethasone. In this case report, doctors used it as a salvage treatment after other therapies failed. It brought the patient's disease under control and led to remission at a 12-month follow-up.
Did the treatment cause the remission?
We can't say that. This is a single case report, so it only shows that remission followed the RPAD treatment. There was no comparison group, and the authors say no causal conclusion can be drawn. The findings can't be generalized to other TAFRO patients.
Were there side effects?
The report doesn't say. It lists no adverse events, no serious adverse events, and no information on tolerability or discontinuations. That doesn't mean there were none, only that this case report didn't report them. Ask your doctor about the risks of any chemotherapy regimen.
What treatments were tried before RPAD?
The patient first received high-dose corticosteroids, intravenous immunoglobulin, and a combination of dexamethasone and ruxolitinib. He didn't respond to any of them. RPAD was then used as a salvage option. If you or someone you know has TAFRO syndrome, talk with a specialist about which approaches fit your situation.
